Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$2.19
-0.07-3.10%
At close: -
$2.35
0.167.31%
After Hours: 5:18 PM EDT
Comments
Loading...
Aprea Therapeutics Analyst Ratings and Price Targets | NASDAQ:APRE | Benzinga
Aprea Therapeutics Inc has a consensus price target of $15.67 based on the ratings of 3 analysts. The high is $20 issued by HC Wainwright & Co. on January 15, 2025. The low is $11 issued by Wedbush on August 13, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on January 15, 2025, December 17, 2024, and November 18, 2024, respectively. With an average price target of $20 between HC Wainwright & Co., there's an implied 751.06% upside for Aprea Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Wedbush
Maxim Group
1calculated from analyst ratings
Analyst Ratings for Aprea Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 01/15/2025 | Buy Now | 751.06% | HC Wainwright & Co. | Joseph Pantginis46% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 12/17/2024 | Buy Now | 751.06% | HC Wainwright & Co. | Joseph Pantginis46% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 11/18/2024 | Buy Now | 751.06% | HC Wainwright & Co. | Joseph Pantginis46% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2024 | Buy Now | 751.06% | HC Wainwright & Co. | Joseph Pantginis46% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 08/13/2024 | Buy Now | 368.09% | Wedbush | Robert Driscoll45% | $11 → $11 | Reiterates | Outperform → Outperform | Get Alert |
| 08/12/2024 | Buy Now | 751.06% | HC Wainwright & Co. | Joseph Pantginis46% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 06/24/2024 | Buy Now | 751.06% | HC Wainwright & Co. | Joseph Pantginis46% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 06/17/2024 | Buy Now | 751.06% | HC Wainwright & Co. | Joseph Pantginis46% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 751.06% | HC Wainwright & Co. | Joseph Pantginis46% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 368.09% | Wedbush | Robert Driscoll45% | $9 → $11 | Maintains | Outperform | Get Alert |
| 03/26/2024 | Buy Now | 751.06% | HC Wainwright & Co. | Joseph Pantginis46% | $20 → $20 | Maintains | Buy | Get Alert |
| 11/01/2023 | Buy Now | 751.06% | HC Wainwright & Co. | Joseph Pantginis46% | → $20 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | 751.06% | HC Wainwright & Co. | Joseph Pantginis46% | → $20 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 751.06% | HC Wainwright & Co. | Joseph Pantginis46% | → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | 751.06% | HC Wainwright & Co. | Joseph Pantginis46% | → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/10/2023 | Buy Now | 580.85% | Maxim Group | Jason McCarthy42% | → $16 | Initiates | → Buy | Get Alert |
| 10/10/2022 | Buy Now | 27.66% | HC Wainwright & Co. | Joseph Pantginis46% | → $60 | Assumes | → Buy | Get Alert |
| 07/08/2022 | Buy Now | 27.66% | Wedbush | Robert Driscoll45% | → $60 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Aprea Therapeutics (APRE) stock?
The latest price target for Aprea Therapeutics (NASDAQ:APRE) was reported by HC Wainwright & Co. on January 15, 2025. The analyst firm set a price target for $20.00 expecting APRE to rise to within 12 months (a possible 751.06% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aprea Therapeutics (APRE)?
The latest analyst rating for Aprea Therapeutics (NASDAQ:APRE) was provided by HC Wainwright & Co., and Aprea Therapeutics reiterated their buy rating.
When was the last upgrade for Aprea Therapeutics (APRE)?
There is no last upgrade for Aprea Therapeutics
When was the last downgrade for Aprea Therapeutics (APRE)?
There is no last downgrade for Aprea Therapeutics.
When is the next analyst rating going to be posted or updated for Aprea Therapeutics (APRE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aprea Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aprea Therapeutics was filed on January 15, 2025 so you should expect the next rating to be made available sometime around January 15, 2026.
Is the Analyst Rating Aprea Therapeutics (APRE) correct?
While ratings are subjective and will change, the latest Aprea Therapeutics (APRE) rating was a reiterated with a price target of $20.00 to $20.00. The current price Aprea Therapeutics (APRE) is trading at is $2.35, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.